Weight loss drugs with a real shot at fighting obesity
An international clinical trial found that obese adults with heart failure experienced improved symptoms and physical function with semaglutide use.
A GLP-1 receptor against attenuated airway inflammation in a mouse model of aspirin-exacerbated respiratory disease, a sub-type of adult asthma
An international clinical trial found that overweight and obese adults experienced decreased cardiovasular disease risk and related death with semaglutide use.
A chart review study found that diabetic patients with asthma experienced fewer and less severe COPD exacerbations with GLP-1 receptor agonists use.
A chart review study found that diabetic patients with asthma experienced fewer asthma exacerbations with GLP-1 receptor agonists
A predictive study estimated that nearly 1 out of 2 in 2 adults will have obesity and 1 out of 3 adults will have severe obesity by 2030
An international clinical trial showed that overweight or obese adults experienced decreased body weight with semaglutide and lifestyle changes
Obesity is a risk factor for developing asthma, worsening asthma symptoms, and poor asthma control
